Join
Live feed
·
PRReleasevia Quantisnow
Tempest Therapeutics Inc. logo

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

ByQuantisnow·Wall Street's wire, on your screen.
TPST· Tempest Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TPST (Tempest Therapeutics Inc.) and more on Quantisnow.